AGS 004

Drug Profile

AGS 004

Alternative Names: AGS-004; AGS-004-001; Arcelis

Latest Information Update: 20 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Argos Therapeutics Inc; Kirin Holdings Company
  • Developer Argos Therapeutics Inc
  • Class Antivirals; Dendritic cell vaccines; Viral vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 11 Jul 2018 University of North Carolina and National Institute of Allergy and Infectious Diseases terminates the pilot phase I VORVAX trial for HIV-1 infections in USA (PO) (NCT02707900)
  • 16 Feb 2018 Argon Therapeutics receives patent allowance for manufacturing HIV immunotherapy in US
  • 26 Jul 2017 Immunogenicity and adverse events data from a phase I/II trial in HIV-1 infections released by Argos Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top